key: cord-0701709-i7ng9gzw authors: Liang, Xuan; Shi, Li; Wang, Ying; Xiao, Wenwei; Duan, Guangcai; Yang, Haiyan; Wang, Yadong title: The association of hypertension with the severity and mortality of COVID-19 patients: evidence based on adjusted effect estimates date: 2020-06-25 journal: J Infect DOI: 10.1016/j.jinf.2020.06.060 sha: 56a8d5fce56da8b4aee1be1fb47e5dc418332132 doc_id: 701709 cord_uid: i7ng9gzw nan Previous studies have shown that common comorbidities were significantly associated with the increased risk of adverse outcomes in patients with coronavirus disease 2019 (1) . As we know, hypertension was the most common comorbidities among COVID-19 patients (2) . Recently, a paper in the Journal of Infection by Zheng et al (3) has reported that the proportion of hypertension was significantly higher in critical/mortal patients compared to the non-critical patients (hypertension: odds ratio (OR) = 2.72, 95%: confidence interval (CI) 1.60-4.64, P = 0.0002). However, the findings were based on unadjusted effect estimates. It was worth mentioning that the data based on unadjusted effect estimates indicated hypertension was an important risk factor for the adverse outcomes of COVID-19 patients, but the pooled effects based on adjusted effect estimates were significantly reduced or even disappeared in several studies (4) (5) (6) (7) (8) . For instance, in the study of Wang et al., univariate analysis showed that hypertension was a risk factor for death in patients with , while multivariate analysis showed that hypertension was not significantly associated with the risk of mortality (OR= 1.099, 95% CI: 0.264-4.580) (7). Similarly, univariate analysis in Cummings et al. indicated that hypertension was significantly associated with patient death (hazard ratio (HR) = 2.24, 95% CI: 1.40-3.59), but this association disappeared in the multivariate analysis (HR = 1.58, 95% CI: 0.89-2.81) (5) . The same findings were also observed in Wang et al.'s study (8) . This meant that the association of hypertension with the adverse outcomes of COVID-19 patients might be affected by various factors such as age, gender and other comorbidities. Therefore, it is urgently required to clarify the association between hypertension and the adverse outcomes of COVID-19 patients by a systematically quantitative meta-analysis on the basis of the published studies reporting the adjusted effect estimates. Therefore, we systematically searched the electronic databases, including Web of Science, Chinese National Knowledge Infrastructure (CNKI) and PubMed to identify all observational studies published between Jan 1, 2020 and June 15, 2020 that compared outcomes in hospitalized COVID-19 patients with and without hypertension. These search engines used the following two sets of keywords to capture available literature: "Coronavirus 2019, 2019-nCoV, SARS-CoV-2, COVID-19" and "Hypertension". Only articles that reported adjusted effect estimates of hypertension and adverse outcomes (severity including severe and critical, and mortality) in patients with COVID-19 were qualified. All calculations were implemented with Stata 11. 2 software. The pooled OR and pooled HR with their corresponding 95% CI were used to evaluate the risk of adverse outcomes in patients with COVID-19 and hypertension. The degree of heterogeneity between studies was tested using I 2 statistics. The I 2 values were 25%, 50%, and 75%, indicating low, medium, and high heterogeneity, respectively (9). If there was no evidence of between-studies heterogeneity (I 2 ≤ 50%), a fixed-effects model was used to calculate the combined effects. Otherwise, a random-effects model was selected (10). The sensitivity analysis was used to evaluate the robustness of the results. Both Begg's test and Egger's test were used to evaluate publication bias. Overall, 521 documents were initially identified according to our search criteria, and the final analysis included 19 studies of 15,302 patients (4) (5) (6) (7) (8) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . As shown in Table 1 , the median age of COVID-19 patients ranged from 43.9 to 71 years, of which 38.2% had hypertension. The sample size ranged from 63 to 2,877. Seventeen studies were retrospective and two prospective. Totally, our meta-analysis showed that hypertension was significantly associated with the increased risk of adverse outcomes in COVID-19 patients on the basis of 19 studies with 15,302 cases (OR= 1.44, 95% CI [1.24-1.66 ]; I 2 = 41.4%, random-effects model) (Fig. 1A) . Of the 19 studies, 12 reported adjusted OR and 7 reported adjusted HR. Therefore, we conducted a subgroup analysis based on the adjusted OR and adjusted HR. We also found a significant correlation between hypertension and adverse outcomes on the basis of both 12 OR-adjusted studies with 8,173 cases (OR= 1.37, 95% CI [1.08-1.72]; I 2 = 51.9%) and 7 HR-adjusted studies with 7,129 cases (HR= 1.55, 95% CI [1.35-1.78 ]; I 2 = 0.0%) (Fig. 1A) . As shown by the sensitivity analysis, none of the studies had a significant impact on the overall results, which proves the robustness of our results (Fig. 1B) Previous studies have suggested that hypertension was a risk factor for adverse outcomes of COVID-19 patients, but the studies did not consider the effects of confounding factors on the findings (2, (25) (26) (27) (28) . Presently, our results showed that hypertension was significantly associated with the increased risk of adverse outcomes in COVID-19 patients on the basis of the adjusted effect estimates, which suggests that hypertension is an independent risk factor for predicting the severity and mortality of COVID-19 patients. Thus COVID-19 patients with hypertension deserve more clinical attention. It should be acknowledged that some limitations existed in our study. Firstly, the judgment criteria of adverse results in the included studies were not uniform. Secondly, all the included studies reported the adjusted effect estimates, but the confounding factors adjusted in each study were not entirely consistent. Thirdly, the stage of hypertension and whether it is controlled or poorly controlled are also unknown. The included studies did not adequately report data on chronic hypertension medications and therefore these could not be analyzed. In summary, our meta-analysis demonstrated for the first time that hypertension was an independent risk factor for predicting the adverse outcomes of patients with COVID-19. Further well-designed studies with larger sample sizes are required to verify the findings of our present study. Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis Clinical characteristics and risk factors for mortality among inpatients with COVID-19 in Wuhan, China. Clinical and translational medicine course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large US Cohort COVID-19) in Bolivia: An analysis of the first 107 confirmed cases A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. The Journal of infection Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection in Patients with Severe Acute Kidney Injury Novel coronavirus disease 2019: predicting prognosis by using a computed tomography severity score and clinicolaboratory data. Polish archives of internal medicine Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 Risk Factors for Mortality in 244 Older Adults With COVID-19 in Wuhan, China: A Retrospective Study Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19 Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study Comparison of clinical characteristics and outcomes of patients with coronavirus disease 2019 at different ages Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis. Liver international : official journal of the International Association for the Study of the Liver Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging Association of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis All values are n (%), mean (SD) or median (IQR) HTN, hypertension NT-proBNP, amino-terminal pro-brain natriuretic peptide; cTnI, cardiac troponin I; hs-CRP, high-sensitivity C-reactive protein Coronary heart disease CVD, cardiovascular or cerebrovascular disease COPD, chronic obstructive pulmonary disease NLR, neutrophil-to-lymphocyte ratio; BUN, blood urea nitrogen BMI, body mass index; SOFA, Sequential Organ Failure Assessment percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)